Afami-cel provides a novel treatment option for rare sarcoma subtypes

Peter Sidaway

DOI: https://doi.org/10.1038/s41571-024-00894-y

IF: 78.8

2024-04-20

Nature Reviews Clinical Oncology

Abstract:Patients with metastatic or unresectable synovial sarcoma or myxoid round cell liposarcoma (comprising 5–10% of all soft-tissue sarcomas) typically have limited long-term survival, especially after disease recurrence on first-line therapy. Now, data from the phase II SPEARHEAD-1 trial testing afamitresgene autoleucel (afami-cel), a CD4 + and CD8 + T cell product transduced with an affinity-enhanced MAGE-A4-specific T cell receptor, provide promising evidence of safety and efficacy in this setting. At a median follow-up duration of 32.6 months, ORR was 37% (95% CI 24–51%), thus exceeding the prespecified null hypothesis (ORR of 18%) and meeting the primary end point. No complete responses were observed. ORRs for patients with synovial sarcoma ( n = 44) and myxoid round cell liposarcoma ( n = 8) were 39% and 25%, respectively. These patients had median response durations of 11.6 months and 4.2 months. Median progression-free survival in the entire cohort was 3.7 months and median overall survival 16.9 months. Not requiring bridging therapy, a MAGE A4 expression H score of ≥200 and a baseline sum of target lesions of <100 mm were all associated with improved ORRs.

oncology